Gary Unzeitig

3.4k total citations
28 papers, 855 citations indexed

About

Gary Unzeitig is a scholar working on Oncology, Cancer Research and Genetics. According to data from OpenAlex, Gary Unzeitig has authored 28 papers receiving a total of 855 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 15 papers in Cancer Research and 9 papers in Genetics. Recurrent topics in Gary Unzeitig's work include Breast Cancer Treatment Studies (13 papers), HER2/EGFR in Cancer Research (7 papers) and BRCA gene mutations in cancer (6 papers). Gary Unzeitig is often cited by papers focused on Breast Cancer Treatment Studies (13 papers), HER2/EGFR in Cancer Research (7 papers) and BRCA gene mutations in cancer (6 papers). Gary Unzeitig collaborates with scholars based in United States, Mexico and Switzerland. Gary Unzeitig's co-authors include Matthew J. Ellis, Kelly K. Hunt, Vera J. Suman, John A. Olson, Mark A. Watson, Jeremy Hoog, Gildy V. Babiera, Lin Li, Joseph M. Guenther and Marilyn Leitch and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Gary Unzeitig

27 papers receiving 838 citations

Peers

Countries citing papers authored by Gary Unzeitig

Since Specialization

Citations

This map shows the geographic impact of Gary Unzeitig's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gary Unzeitig with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gary Unzeitig more than expected).

Fields of papers citing papers by Gary Unzeitig

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gary Unzeitig. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gary Unzeitig. The network helps show where Gary Unzeitig may publish in the future.

Co-authorship network of co-authors of Gary Unzeitig

This figure shows the co-authorship network connecting the top 25 collaborators of Gary Unzeitig. A scholar is included among the top collaborators of Gary Unzeitig based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gary Unzeitig. Gary Unzeitig is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Local-Regional Recurrence After Neoadjuvant Endocrine Therapy: Data from ACOSOG Z1031 (Alliance), a Randomized Phase 2 Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women with Estrogen Receptor-Positive Clinical Stage 2 or 3 Breast Cancer 2023 ·Annals of Surgical Oncology ·Kelly K. Hunt, Vera J. Suman, Hannah F. Wingate, A. Marilyn Leitch, Gary Unzeitig, Judy C. Boughey, Funda Meric‐Bernstam, Matthew J. Ellis, John A. Olson	9
2	The Influence of Vitamin D on Mammographic Density: Results from CALGB 70806 (Alliance) a Randomized Clinical Trial 2021 ·Cancer Prevention Research ·Marie Wood, Heshan Liu, (unknown), David Zahrieh, (unknown), Sin‐Ho Jung, Patricia J. Zekan, Margaret Kemeny, (unknown), (unknown), Gary Unzeitig, Candace S. Johnson, Judy E. Garber, James R. Marshall, Isabelle Bedrosian	6
3	ALTERNATE: Neoadjuvant endocrine treatment (NET) approaches for clinical stage II or III estrogen receptor-positive HER2-negative breast cancer (ER+ HER2- BC) in postmenopausal (PM) women: Alliance A011106. 2020 ·Journal of Clinical Oncology ·X. Cynthia, Vera J. Suman, A. Marilyn Leitch, Souzan Sanati, Kiran Vij, Gary Unzeitig, Jeremy Hoog, Mark A. Watson, Olwen Hahn, J. Michael Guenther, Abigail S. Caudle, Travis Dockter, Larissa A. Korde, Anna Weiss, Kelly K. Hunt, Clifford A. Hudis, Eric P. Winer, Ann H. Partridge, Lisa A. Carey, Matthew J. Ellis, (unknown)	27
4	Clinical Trials for the Surgical Oncologist: Opportunities and Hurdles 2020 ·Annals of Surgical Oncology ·Ko Un Park, Eleftherios P. Mamounas, Matthew H. G. Katz, Gary Unzeitig, Darren R. Carpizo, Y. Nancy You, Amanda B. Francescatti, Kelly K. Hunt, Judy C. Boughey	3
5	A randomized study to prevent lymphedema in women treated for breast cancer: CALGB 70305 (Alliance) 2020 ·Cancer ·Electra D. Paskett, Jennifer Le‐Rademacher, Jill M. Oliveri, Heshan Liu, Drew K. Seisler, Jeffrey A. Sloan, Jane M. Armer, Michelle J. Naughton, Karen Hock, Michael Schwartz, Gary Unzeitig, Marianne Melnik, Xuhui Lee, Gini F. Fleming, John R. Taylor, Charles L. Loprinzi	19
6	Pathogenic and likely pathogenic variants in PALB2 , CHEK2 , and other known breast cancer susceptibility genes among 1054 BRCA ‐negative Hispanics with breast cancer 2019 ·Cancer ·Jeffrey N. Weitzel, Susan L. Neuhausen, Aaron W. Adamson, Shu Tao, Charité Ricker, Asaf Maoz, (unknown), Bita Nehoray, Sharon Sand, Linda Steele, Gary Unzeitig, Nancy Feldman, Amie Blanco, Donglei Hu, Scott Huntsman, Danielle Castillo, Christopher A. Haiman, Thomas P. Slavin, Elad Ziv	36
7	Disease-Free and Overall Survival Among Patients With Operable HER2-Positive Breast Cancer Treated With Sequential vs Concurrent Chemotherapy 2018 ·JAMA Oncology ·Aman U. Buzdar, Vera J. Suman, Funda Meric‐Bernstam, A. Marilyn Leitch, Matthew J. Ellis, Judy C. Boughey, Gary Unzeitig, Melanie Royce, Kelly K. Hunt	9
8	Abstract P6-09-05: Factors associated with the uptake of risk-reducing surgeries among Hispanic women at high risk of breast and ovarian cancer 2018 ·Cancer Research ·Yanin Chávarri-Guerra, Kai Yang, Ian K. Komenaka, Sandra M. Brown, (unknown), (unknown), Polly Duncan, (unknown), Pamela Ganschow, (unknown), Gary Unzeitig, (unknown), (unknown), Thomas Slavin, Bita Nehoray, (unknown), Raúl Méjía, Sharon Sand, Kathleen R. Blazer, Jeffrey N. Weitzel	1
9	Genomic characterization of HER2-positive breast cancer and response to neoadjuvant trastuzumab and chemotherapy—results from the ACOSOG Z1041 (Alliance) trial 2017 ·Annals of Oncology ·Robert Lesurf, Obi L. Griffith, Malachi Griffith, Jasreet Hundal, Lee Trani, Mark A. Watson, Rebecca Aft, Matthew J. Ellis, (unknown), Vera J. Suman, Funda Meric‐Bernstam, A. Marilyn Leitch, Judy C. Boughey, Gary Unzeitig, Aman U. Buzdar, Kelly K. Hunt, Elaine R. Mardis	47
10	Effect of Vitamin D Supplementation on Breast Cancer Biomarkers: CALGB 70806 (Alliance) Study Design and Baseline Data. 2016 ·PubMed ·(unknown), Sin‐Ho Jung, Heshan Liu, Drew K. Seisler, (unknown), Patricia J. Zekan, (unknown), Gary Unzeitig, Judy E. Garber, James R. Marshall, Marie Wood	2
11	Abstract P4-11-13: Validation of the preoperative endocrine prognostic index in the ACOSOG (Alliance) Z1031 neoadjuvant aromatase inhibitor trial 2015 ·Cancer Research ·Souzan Sanati, Vera J. Suman, Rodrigo Gonçalves, Katherine DeSchryver, X. Cynthia, Jeremy Hoog, Erika C. Crouch, Michael Barnes, Gary Unzeitig, A. Marilyn Leitch, Kelly K. Hunt, Matthew J. Ellis	2
12	Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial 2013 ·The Lancet Oncology ·Aman U. Buzdar, Vera J. Suman, Funda Meric‐Bernstam, A. Marilyn Leitch, Matthew J. Ellis, Judy C. Boughey, Gary Unzeitig, Melanie Royce, Linda McCall, Michael S. Ewer, Kelly K. Hunt	120
13	ACOSOG Z1041 (Alliance): Definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC → P+T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P+T → FEC+T) in HER2+ operable breast cancer. 2013 ·Journal of Clinical Oncology ·Aman U. Buzdar, Vera J. Suman, Funda Meric‐Bernstam, A. Marilyn Leitch, Matthew J. Ellis, Judy C. Boughey, Gary Unzeitig, Melanie Royce, Kelly K. Hunt	10
14	ACOSOG Z1041 (Alliance): Cardiac events (CE) among those receiving neoadjuvant anthracyclines (A) and taxanes with trastuzumab (T) for HER2+ breast cancer. 2013 ·Journal of Clinical Oncology ·Michael S. Ewer, Vera J. Suman, Aman U. Buzdar, Linda McCall, Funda Meric‐Bernstam, A. Marilyn Leitch, Matthew J. Ellis, Judy C. Boughey, Gary Unzeitig, Melanie Royce, Kelly K. Hunt	4
15	Abstract PD07-01: Z1031B Neoadjuvant Aromatase Inhibitor Trial: A Phase 2 study of Triage to Chemotherapy Based on 2 to 4 week Ki67 level > 10%. 2012 ·Cancer Research ·(unknown), Vera J. Suman, Lisa McCall, Rui Luo, (unknown), Arjen Brink, Mark Watson, Chuang Ma, Gary Unzeitig, (unknown), Pat W. Whitworth, Gildy V. Babiera, Michael Guenther, Zoneddy Dayao, M. Leitch, David M. Ota, John A. Olson, Katie N. Hunt, C Allred	12
16	Prevalence and Type ofBRCAMutations in Hispanics Undergoing Genetic Cancer Risk Assessment in the Southwestern United States: A Report From the Clinical Cancer Genetics Community Research Network 2012 ·Journal of Clinical Oncology ·Jeffrey N. Weitzel, Jessica Clague, Arelis Martir-Negron, (unknown), Josef Herzog, Charité Ricker, (unknown), (unknown), Paul R. Duncan, Gary Unzeitig, Juan‐Sebastian Saldivar, Mary Beattie, Nancy Feldman, Sharon Sand, (unknown), Deborah I. Barragan, Esther M. John, Susan L. Neuhausen, Garrett P. Larson	115
17	Prevalence and ancestral origin of BRCA mutations in the Hispanic population: Insights for ancestry-informed genetic cancer risk assessment. 2011 ·Journal of Clinical Oncology ·Jeffrey N. Weitzel, (unknown), (unknown), Arelis Martir-Negron, Josef Herzog, Charité Ricker, Jo Congleton, (unknown), Paul R. Duncan, Gary Unzeitig, Juan‐Sebastian Saldivar, (unknown), Nancy Feldman, Sharon Sand, (unknown), Esther M. John, Christopher Haiman, (unknown), Susan L. Neuhausen, Garrett P. Larson	1
18	Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor–Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype—ACOSOG Z1031 2011 ·Journal of Clinical Oncology ·Matthew J. Ellis, Vera J. Suman, Jeremy Hoog, Lin Li, Jacqueline Snider, Aleix Prat, Joel S. Parker, Jingqin Luo, Katherine DeSchryver, D. Craig Allred, Laura J. Esserman, Gary Unzeitig, Julie Margenthaler, Gildy V. Babiera, P. Kelly Marcom, Joseph M. Guenther, Mark A. Watson, Marilyn Leitch, Kelly K. Hunt, John A. Olson	365
19	ACOSOG Z1031: A randomized phase II trial comparing exemestane, letrozole, and anastrozole in postmenopausal women with clinical stage II/III estrogen receptor-positive breast cancer. 2010 ·Journal of Clinical Oncology ·Matthew J. Ellis, (unknown), Gary Unzeitig, P. Kelly Marcom, J. Michael Guenther, (unknown), D. Craig Allred, VJ Suman, Karen A. Hunt, John A. Olson	19
20	How a surgeon in the boonies becomes a researcher and regional expert. 2007 ·PubMed ·Gary Unzeitig	0

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact